Risk-reducing therapies, such as tamoxifen, raloxifene, or aromatase inhibitors, should be administered to women who are at an increased risk for breast cancer and at a low risk for adverse events associated with these medications.
More From BioPortfolio on "USPSTF Releases Final Recommendation on Treatments for Reducing Breast Cancer Risk"